RSH on cusp of big Chinese deal
Volume just starting to pick up after a long consolidation..
Only $20m mkt cap - a few years back it ran from these levels to 80c in months...
The exec chairman just got granted 10m options at 7.5 c and another 10m options at 10c
Comparable RAP went from similar levels and now a $200m diluted mkt cap!!
So something must be happening...
Check out below:
FINALISED: 23-05-17 PUBLISHED: 23-05-17
Is RSH about to Strike a Major Chinese Partnership Deal for its Asthma Tech?
Innovative MedTech company, Respiri Ltd (ASX:RSH), with its portfolio of asthma and chronic pulmonary disease (COPD) devices and software, is tackling a very real and global problem: asthma and chronic pulmonary disease.
RSH is progressing its path to commercialisation with sales of its next generation wheeze detection and monitoring device, AirSonea™. RSH was recently given the go ahead to distribute the device in the European market, including into one of its three previously identified target markets — the UK.
This crucial step validates the AirSonea technology, which RSH is seeking to develop into the world-leading, gold standard in non-invasive, asthma management solution.
With over 330 million people worldwide suffering from asthma alone, the global market for asthma and chronic obstructive pulmonary disease (COPD) is estimated to hit $47 billion this year.
That number and the fact that 250,000 people die prematurely each year from asthma indicates there is a large and growing addressable market for a company capable of positively transforming asthma monitoring for sufferers and carers alike: one that lets asthmatics monitor their symptoms, take proactive precautions including better medication management, and ultimately gain peace of mind and a better quality of life.
The $20 million capped RSH is leaping towards commercialisation and is directing its focus on securing partnership agreements by the end of May to help launch a new generation of its continuous monitoring system in a large overseas market.
At the same time, it should be noted that this company represents a speculative investment and those considering this stock for their portfolio should seek professional financial advice before making a decision.
These highly anticipated partnership agreements will involve the production of the company’s next generation device, plus sales and distribution agreements.
So with a raft of news to come, let’s catch up with…
Respiri Limited ASX:RSH New Articles Straight to Your Inbox
